The Psychedelics Newsletter

How psychedelics could help those living with alcohol use disorders, Psilocybin therapy for anorexia nervosa, Oregon's lucrative psychedelic industry.

Neuroimaging study measures brain activity under psychedelic medicines, Awakn completes the sale of Awakn clinics in Norway, Navigating the industry shakeout.

Psychedelics should be at forefront of EU mental health efforts, urge PAREA, Psilocybin in the treatment of anorexia nervosa, A drug developer's guide to navigating psychedelic trials.

PSYCH Symposium: shifting perceptions, in conversation with Robin Carhart-Harris, The impact of SSRIs on psilocybin-assisted therapy, Psychedelic solutions for police and society.

PSYCH Symposium: exploring psychedelic medicine, Advancing psychedelic healthcare in Europe, Neuroimaging and psychedelic medicine.

Exploring eating disorders and psychedelics, Awakn Life Sciences completes sale of Awakn clinics, Innovating the delivery of psychedelic-assisted therapy.

FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs, MHRA approves psilocin trial for major depressive disorder, 61% of Americans support legalisation of psychedelic therapy.

Psych Capital acquires Shortwave Pharma, The future of psychedelic medicine in the EU, Psychedelic medicines and pro-social preferences.

PSYCH Symposium: London 2023 - ticket prices rise at midnight, Negev Capital confident big pharma will embrace psychedelics, Fresh insights into the mechanism of action of psychedelic medicines.

CDPRG discusses the UK’s Reschedule Psilocybin campaign, MP Charlotte Nichols speaking at PSYCH Symposium: London 2023, Reunion Neuroscience to be acquired for US$13.1 million.

MEP action group launches in Europe, First Phase III study with psilocybin underway, UK government pledges £650m for life sciences.

What to expect at PSYCH Symposium: London 2023, UK sees call to review psilocybin scheduling, US federal agency to fund psychedelic research.